.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,849,240

« Back to Dashboard

Details for Patent: 5,849,240

Title: Method of preparing sustained release pharmaceutical compositions
Abstract:A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.
Inventor(s): Miller; Ronald Brown (Basel, CH), Leslie; Stewart Thomas (Cambridge, GB2), Malkowska; Sandra Therese Antoinette (Cambridge, GB2), Prater; Derek Allan (Cambridge, GB2), Knott; Treavor John (Essex, GB2), Heafield; Joanne (Cambridge, GB2), Challis; Deborah (Kent, GB2)
Assignee: Euro-Celtique, S.A. (Luxembourg, LU)
Filing Date:Feb 27, 1996
Application Number:08/607,852
Claims:1. A process for the manufacture of controlled release particles, which comprises:

(a) mechanically working in a high-speed mixer, a mixture of a particulate drug and a particulate, hydrophobic and/or hydrophilic fusible carrier or diluent having a melting point of 35.degree. to 150.degree. C. and optionally a release control component comprising water-soluble fusible material or a particulate, soluble or insoluble organic or inorganic material, at a speed and energy input and at a drug to fusible carrier(s) ratio and by a process which allows the carrier or diluent to melt or soften to form agglomerates of irregular shape;

(b) breaking down the irregular shaped agglomerates to give controlled release particles; and optionally

(c) continuing mechanically working optionally with the addition of a low percentage of the carrier or diluent; and optionally

(d) repeating steps (c) and possibly (b) one or more times.

2. A process according to claim 1, wherein during the mechanical working, step (c), heat is supplied thereto by microwave radiation.

3. A process according to claim 2, wherein only part of the heating is supplied by microwave radiation.

4. A process according to claim 1, wherein said drug is morphine, tramadol, hydromorphone, oxycodone, diamorphine or a pharmaceutically acceptable salt of any one of these.

5. A process according to claim 1, wherein said hydrophobic fusible carrier or diluent is a wax selected from the group consisting of hydrogenated vegetable oil, hydrogenated castor oil, Beeswax, Carnauba wax, microcrystalline wax and glycerol monostearate.

6. A process according to claim 1, wherein said water-soluble fusible material optionally included in the mixture in step (a) is PEG having a molecular weight of from about 1,000 to about 20,000.

7. A process according to claim 6, wherein said PEG has a molecular weight of from about 1,000 to about 6,000.

8. A process according to claim 6, wherein said water-soluble fusible material is a poloxamer.

9. A process according to claim 1, wherein the fusible carrier or diluent is added stepwise during mechanical working.

10. A process according to claim 1, wherein said process further comprises adding particulate fusible material in the amount of between 10% and 99% w/w to said irregular-shaped agglomerates for mechanically working said agglomerates and said added particulate fusible material.

11. A process according to claim 10, wherein the hydrophobic agent is hydrogenated vegetable oil, and said hydrophobic agent comprises at least 25% of said mixture.

12. A process according to claim 11, wherein the hydrogenated vegetable oil comprises about 10% of said mixture; and said hydrophilic agent is PEG which comprises from about 0.047% to about 0.6% of said mixture by weight, and wherein the drug is morphine sulfate.

13. A process according to claim 11, wherein the hydrogenated vegetable oil comprises from about 25% to about 66.7% of said mixture and wherein the drug is tramadol HCl.

14. A process according to claim 11, wherein the hydrogenated vegetable oil comprises about 50% of said mixture and the drug is diamorphine hydrochloride.

15. A process according to claim 1, wherein said drug is an opioid.

16. A process according to claim 1, wherein said release control component is selected from the group consisting of polyethylene glycol, dicalcium phosphate, calcium sulfate, talc, colloidal anhydrous silica, lactose, poloxamers, microcrystalline cellulose, starch, hydroxypropyl-cellulose and hydroxypropylmethylcellulose.

17. A process according to claim 1, wherein the particles further comprise a release control component selected from the group consisting of a water soluble fusible material, a particulate soluble organic material, a particulate soluble inorganic material, a particulate insoluble organic material, a particulate insoluble inorganic material, and mixtures thereof.

18. A process according to claim 12, wherein the morphine sulfate is sufficient to provide a plasma concentration of morphine effective to provide an analgesic effect for about 24 hours after administration of said dosage form.

19. A process according to claim 1, wherein said particles are compressed into a tablet.

20. A process according to claim 1, wherein said particles are disposed in a capsule.

21. A process according to claim 1, wherein the particles produced after the granulation process are in the size range 0.5 to 2 mm.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc